Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice
- 1 June 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (6) , 1912-1916
- https://doi.org/10.1128/aac.00193-08
Abstract
Treatment with rifampin-clarithromycin or moxifloxacin-clarithromycin for 8 weeks displayed promising bactericidal activity against Mycobacterium ulcerans in mice; none of the mice treated with rifampin-clarithromycin relapsed, whereas 59% of those treated with moxifloxacin-clarithromycin relapsed after treatment was stopped. The bactericidal and sterilizing activities of the five-times-weekly (5/7) administration of 5 mg of rifapentine/kg of body weight, either alone or in combination, were virtually identical to those of the corresponding regimens with 10 mg of rifampin/kg of body weight; however, because of the long half-life of rifapentine, accumulation of the drug after 5/7 administration is a concern. The bactericidal activity of 20 mg/kg rifapentine in monotherapy or 20 mg/kg rifapentine in combination with 150 mg/kg streptomycin or 200 mg/kg moxifloxacin administered twice weekly was as effective as the corresponding regimens containing 10 mg/kg rifampin administered 5/7, suggesting that Buruli ulcer might be treated with intermittently administered rifapentine-containing combinations.Keywords
This publication has 16 references indexed in Scilit:
- Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease)Antimicrobial Agents and Chemotherapy, 2007
- Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in MiceAntimicrobial Agents and Chemotherapy, 2007
- Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-AmikacinAntimicrobial Agents and Chemotherapy, 2007
- Dosing Schedules of 6-Month Regimens and Relapse for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Potent Twice-Weekly Rifapentine-containing Regimens in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulceransAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics of Rifapentine in ChildrenThe Pediatric Infectious Disease Journal, 2006
- Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household ContactsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazidThe Lancet, 1999
- Development of rifapentine: the way ahead.1998